MRK Merck & Co., Inc. Loading... : Bullish and Bearish Analyst Opinions
From GILD earnings callsLoading chart...
Top Calls
Feed
20:30
Aug 04
Aug 04
The HIV PrEP market itself is growing rapidly, and Gilead's overall PrEP business is now at a $4 billion annual run rate, significantly outpacing the market. — Gilead is expanding the entire PrEP market while gaining share, potentially impacting competitors like Merck's future prevention products.
HIGH
20:30
May 07
May 07
Gilead is shifting its commercial strategy in HIV treatment by actively marketing a new brand (BicLen) that will cannibalize its flagship Biktarvy, aiming to capture patients who would otherwise switch to competitors. — This is a defensive launch to protect market share; while it may cannibalize Biktarvy, it is expected to keep higher-value patients within Gilead's portfolio.
HIGH
21:30
Feb 10
Feb 10
Gilead is advancing Trodelvi in combination with Merck's Keytruda (pembrolizumab), positioning both companies in the frontline TNBC market.
HIGH
About MRK Analyst Coverage
Buzzberg tracks MRK (Merck & Co., Inc.) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 3 total trade ideas tracked. Past 7 days: 1 watch. Latest voices: Dietmar Berger.